BOSTON (AP) — BOSTON (AP) — Verve Therapeutics Inc. (VERV) on Wednesday reported a loss of $31 million in its first quarter.
The Boston-based company said it had a loss of 35 cents per share.
The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 71 cents per share.
The biotechnology firm posted revenue of $33 million in the period, also exceeding Street forecasts. Three analysts surveyed by Zacks expected $7.1 million.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on VERV at https://www.zacks.com/ap/VERV
Copyright © 2025 The Associated Press. All rights reserved. This material may not be published, broadcast, written or redistributed.
